HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ipsapirone and ketanserin protects against circulatory shock, intracranial hypertension, and cerebral ischemia during heatstroke.

Abstract
We assess the effects of ipsapirone (a 5-HT1A receptor agonist), ketanserin (a 5-HT2A receptor antagonist), (-)-pindolol (a 5-HT1A receptor antagonist), and DOI (a 5-HT2A receptor agonist) on heatstroke in a rat model. Animals, under urethane anesthesia, were exposed to high ambient temperature of 42 degrees C until mean arterial pressure and local cerebral blood flow in the striatum began to decrease, which was arbitrarily defined as the onset of heatstroke. Normothermic controls were exposed to room temperature of 24 degrees C. In rats treated with normal saline immediately before the initiation of heat stress, the values for survival time were found to be 21 to 25 min. Systemic administration of ipsapirone (10 mg/kg) or ketanserin (2 mg/kg) immediately before the initiation of heat stress significantly increased the survival time to new values of 92 to 104 min. Combined treatment with ipsapirone and ketanserin had additive effects (survival time of 156-194 min). In contrast, systemic administration of (-)-pindolol (2 mg/kg) or DOI (2 mg/kg) significantly decreased the survival time to new values of 2 to 3 min. In vehicle-treated heatstroke rats, the values for core temperature, intracranial pressure, and the extracellular levels of cellular ischemia (e.g., glutamate and lactate/pyruvate ratio) or damage (e.g., glycerol) markers and neuronal damage scores in striatum were significantly higher than those of normothermic controls. On the other hand, the values for mean arterial pressure, cerebral perfusion pressure, cerebral blood flow, and brain partial pressure of O2 were significantly lower than those of normothermic controls. The heatstroke-induced hyperthermia, arterial hypotension, intracranial hypertension, cerebral hypoperfusion and hypoxia, and increased levels of cellular ischemia and damage markers in striatum were all significantly attenuated by prior administration of ipsapirone or ketanserin. The present results strongly suggest that previous activation of 5-HT1A receptors or antagonism of 5-HT2A receptors protects against heatstroke by reducing circulatory shock and cerebral ischemia, whereas prior antagonism of 5-HT1A receptors or activation of 5-HT2A receptors exacerbates heatstroke.
AuthorsChing-Ping Chang, Sheng-Hsien Chen, Mao-Tsun Lin
JournalShock (Augusta, Ga.) (Shock) Vol. 24 Issue 4 Pg. 336-40 (Oct 2005) ISSN: 1073-2322 [Print] United States
PMID16205318 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Lactates
  • Pyrimidines
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • Lactic Acid
  • Urethane
  • Glutamic Acid
  • ipsapirone
  • Pyruvic Acid
  • Ketanserin
  • Titanium
  • Glycerol
  • Oxygen
Topics
  • Anesthesia
  • Animals
  • Brain (metabolism)
  • Brain Ischemia (pathology, prevention & control)
  • Corpus Striatum (chemistry, metabolism)
  • Disease Models, Animal
  • Glutamic Acid (chemistry, pharmacology)
  • Glycerol (chemistry)
  • Heat Stroke (drug therapy, pathology, prevention & control)
  • Hot Temperature
  • Hypertension
  • Hypoxia
  • Intracranial Hypertension (pathology, prevention & control)
  • Ketanserin (pharmacology)
  • Lactates (chemistry)
  • Lactic Acid (chemistry, pharmacology)
  • Models, Statistical
  • Neurons (metabolism)
  • Oxygen (metabolism)
  • Pressure
  • Pyrimidines (pharmacology)
  • Pyruvic Acid (chemistry, pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Serotonin Antagonists (pharmacology)
  • Serotonin Receptor Agonists (pharmacology)
  • Shock (pathology)
  • Temperature
  • Time Factors
  • Titanium (chemistry)
  • Urethane (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: